A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Phase 3
18+
Female only
1 site in FL
About this study
This Phase 3 study is testing Bevacizumab in people with neoplasms. The primary outcome being measured is Progression-Free Survival (PFS).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
bevacizumab
infusion
Primary: Progression-Free Survival (PFS)
Secondary: Change From Baseline in Abdominal/Gastrointestinal (GI) Symptoms Combined Score Using the EORTC QLQ-Ovarian Cancer Module 28 (OV28), Change From Baseline in Global Health Status/Quality of Life (GHS/QoL) Combined Score (Items 29 and 30) Using the European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30), Change From Baseline in Physical Functioning Combined Score (Items 1 to 5) Using EORTC QLQ-C30, Change From Baseline in Role Functioning Combined Score (Items 6 and 7) Using EORTC QLQ-C30, Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE), Overall Survival (OS), Progression-Free Survival 2 (PFS2)
Oncology